Cargando…

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

BACKGROUND: Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This method carries significant intra- and inter-observer variability. Automatic scoring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinn, Hans-Peter, Schneeweiss, Andreas, Keller, Marius, Schlombs, Kornelia, Laible, Mark, Seitz, Julia, Lakis, Sotirios, Veltrup, Elke, Altevogt, Peter, Eidt, Sebastian, Wirtz, Ralph M., Marmé, Frederik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307758/ https://www.ncbi.nlm.nih.gov/pubmed/28193205 http://dx.doi.org/10.1186/s12885-017-3111-1

Ejemplares similares

Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens
por: Laible, Mark, et al.
Publicado: (2016)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry
por: Wirtz, Ralph M., et al.
Publicado: (2016)

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies
por: Breyer, Johannes, et al.
Publicado: (2017)

Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression
por: Mukhopadhyay, Madhumita, et al.
Publicado: (2017)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
por: Selmani, Zohair, et al.
Publicado: (2022)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters
por: K, Sajitha, et al.
Publicado: (2022)

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer
por: Besusparis, Justinas, et al.
Publicado: (2016)

Ki‐67 assessment—agreeability between immunohistochemistry and flow cytometry in canine lymphoma
por: Rigillo, Antonella, et al.
Publicado: (2021)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
por: Hadad, Sirwan M., et al.
Publicado: (2016)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Assessment of p16 and Ki67 Immunohistochemistry Expression in Squamous Intraepithelial Lesion with Cytohistomorphological Correlation
por: Ghosh, Apurv, et al.
Publicado: (2020)

Prognostic value of the immunohistochemistry correlation of Ki-67 and p53 in squamous cell carcinomas of the larynx
por: Rodrigues, Ricardo Boose, et al.
Publicado: (2015)

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
por: Tuominen, Vilppu J, et al.
Publicado: (2010)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China
por: Pu, Tianjie, et al.
Publicado: (2019)

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®
por: Varga, Zsuzsanna, et al.
Publicado: (2017)

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2016)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Steroid hormone receptors ERα and PR characterised by immunohistochemistry in the mare adrenal gland
por: Alm, Ylva Hedberg, et al.
Publicado: (2009)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma
por: Uguen, Arnaud, et al.
Publicado: (2015)

Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer
por: Serna, Garazi, et al.
Publicado: (2020)

Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study
por: Afkari, Hanif, et al.
Publicado: (2021)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue
por: Hartmann, Kerstin, et al.
Publicado: (2018)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non–muscle-invasive Bladder Cancer: A Case Report
por: Weiß, Sarah, et al.
Publicado: (2021)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p3qp8b4lshp6fhg2qkt167ohf7